Novigenix Buys Colorectal Cancer Test

February 13, 2015

Swiss molecular diagnostics firm Novigenix announced Thursday that it purchased Diagnoplex’s Colox colorectal cancer test for an undisclosed sum.

Colox detects colorectal cancer from a drop of blood by checking the gene expression signature of 29 genes in peripheral blood mononuclear cells. The test is expected to allow earlier diagnosis and treatment of the disease — and thereby cut mortality rates — by increasing compliance with routine screening, Lausanne, Switzerland-based Novigenix said.

The product was evaluated in a clinical trial at Centre Hospitalier Universitaire Vaudois in Lausanne and is CE-marked for sale in Europe. Novigenix plans to initially make Colox available within Switzerland and then roll it out across Europe via partnerships. — Elizabeth Orr